Host Cellular RNA Helicases Regulate SARS-CoV-2 Infection
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2 has a large RNA genome, of approximately 30 kb. To regulate and maintain such a large viral RNA genome, host RNA helicases may be involved in SARS-CoV-2 replication.
Article activity feed
-
-
SciScore for 10.1101/2021.06.29.450452: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Pre-cleared supernatants were incubated with 5 μg of anti-SARS-CoV-2 nucleocapsid antibody mixture (GTX135357 and GTX632269 [6H3]; GeneTex), anti-DDX21 (A300-627A; Bethyl Lab), anti-DDX6 (A300-460A; Bethyl Lab), or anti-MOV10 (A301-571A; Bethyl Lab) antibody at 4°C for 1 hour (h). anti-SARS-CoV-2 nucleocapsidsuggested: NoneGTX632269suggested: (GeneTex Cat# GTX632269, RRID:AB_2888304)anti-DDX21suggested: (Bethyl Cat# A300-627A, RRID:AB_513601)anti-DDX6suggested: (Bethyl Cat# A300-460A, …SciScore for 10.1101/2021.06.29.450452: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Pre-cleared supernatants were incubated with 5 μg of anti-SARS-CoV-2 nucleocapsid antibody mixture (GTX135357 and GTX632269 [6H3]; GeneTex), anti-DDX21 (A300-627A; Bethyl Lab), anti-DDX6 (A300-460A; Bethyl Lab), or anti-MOV10 (A301-571A; Bethyl Lab) antibody at 4°C for 1 hour (h). anti-SARS-CoV-2 nucleocapsidsuggested: NoneGTX632269suggested: (GeneTex Cat# GTX632269, RRID:AB_2888304)anti-DDX21suggested: (Bethyl Cat# A300-627A, RRID:AB_513601)anti-DDX6suggested: (Bethyl Cat# A300-460A, RRID:AB_420926)A301-571A; Bethyl Labsuggested: NoneThe proteins were then subjected to SDS-PAGE, followed by immunoblot analysis using anti-SARS-CoV-2 nucleocapsid (GTX632269 [6H3]), anti-DDX21, anti-DDX6 or anti-MOV10 antibody. anti-SARS-CoV-2 nucleocapsid ( GTX632269suggested: Noneanti-MOV10suggested: NoneThe cells were fixed in 3.6% formaldehyde in phosphate-buffered saline (PBS), permeabilized in 0.1% NP-40 in PBS at room temperature, and incubated with anti-HA antibody (3F10; F. Hoffmann-La Roche AG, Basel, Switzerland) at a 1:300 dilution in PBS containing 3% bovine serum albumin (BSA) at 37°C for 30 min. anti-HAsuggested: NoneWe also used anti-DDX6 (A300-460A; Bethyl Lab), anti-XRN1 (A300-443A; Bethyl Lab), anti-G3BP1 (A302-033A; Bethyl) anti-DDX21 (A300-627A; Bethyl Lab), anti-MOV10 (A301-571A; Bethyl Lab), anti-DDX5 (A300-523A; Bethyl Lab), or anti-SARS-CoV-2 nucleocapsid (ab273434 [6H3]; Abcam or GTX632269 [6H3]; GeneTex) antibodies as primary antibodies. anti-XRN1suggested: (Bethyl Cat# A300-443A, RRID:AB_2219047)anti-G3BP1suggested: (Bethyl Cat# A302-033A, RRID:AB_1576539)anti-DDX5suggested: (Bethyl Cat# A300-523A, RRID:AB_451048)Cells were then stained with Donkey anti-mouse IgG (H+L) secondary antibody, Alexa Fluor 594 conjugate and/or Donkey anti-rabbit or anti-rat IgG (H+L) secondary antibody, Alexa Fluor 488 conjugate (Thermo Fisher Scientific Inc. anti-mouse IgGsuggested: Noneanti-rabbit or anti-rat IgGsuggested: Noneanti-ratsuggested: NoneThe SARS-CoV-2-infected cells were detected using anti-SARS-CoV-2 Spike (GTX632604 [1A9]; GeneTex, Irvine, CA, USA) or anti-SARS-CoV-2 nucleocapsid (ab273434 [6H3]; Abcam or GTX632269 [6H3]; GeneTex) antibodies. anti-SARS-CoV-2suggested: Noneanti-SARS-CoV-2 nucleocapsid (ab273434 [suggested: NoneExperimental Models: Cell Lines Sentences Resources Cell culture: 293T, HepG2, HEK293T ACE2 (SL221 HepG2suggested: NoneHEK293Tsuggested: NonePlasmid construction: To construct pcDNA3-HA-MOV10, a DNA fragment encoding MOV10 was amplified from HuH-7 cDNA by PCR using KOD-Plus DNA polymerase (TOYOBO, Osaka, Japan) and the following pairs of primers: 5’-CGGGATCCAAGATGCCCAGTAAGTTCAGCTG-3’ (Forward), 5’-CCGCTCGAGTCAGAGCTCATTCCTCCACTCTG-3’ (Reverse). HuH-7suggested: CLS Cat# 300156/p7178_HuH7, RRID:CVCL_0336)The lentiviral vector particles were produced by transient transfection of the second-generation packaging construct pCMVΔR8.74 (42, 43) and the VSV-G-envelope-expressing plasmid pMD2G as well as pRDI292 into 293T cells with TransIT-LT1 transfection reagent (Mirus Bio LLC, Madison, WI, USA). 293Tsuggested: CCLV Cat# CCLV-RIE 1018, RRID:CVCL_0063)For infection experiments with SARS-CoV-2 virus, HEK293T ACE2 cells (2×105 cells/well) were plated onto 6-well plates and cultured for 24 h. HEK293T ACE2suggested: NoneActually, 1μl of culture supernatants of SARS-CoV-2-infected VeroE6 TMPRSS2 cells (2.7×108 TCID50/ml) were inoculated. VeroE6 TMPRSS2suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)Recombinant DNA Sentences Resources Plasmid construction: To construct pcDNA3-HA-MOV10, a DNA fragment encoding MOV10 was amplified from HuH-7 cDNA by PCR using KOD-Plus DNA polymerase (TOYOBO, Osaka, Japan) and the following pairs of primers: 5’-CGGGATCCAAGATGCCCAGTAAGTTCAGCTG-3’ (Forward), 5’-CCGCTCGAGTCAGAGCTCATTCCTCCACTCTG-3’ (Reverse). pcDNA3-HA-MOV10suggested: NoneThe obtained DNA fragments were subcloned into either the BamHI-NotI sites of the pcDNA3-HA vector, and the nucleotide sequences were determined by Sanger sequencing. pcDNA3-HAsuggested: RRID:Addgene_78782)We previously described pHA-DDX3 (8–12), pcDNA3-HA-DDX1 and pcDNA3-HA-DDX6 (9). pHA-DDX3suggested: NonepcDNA3-HA-DDX1suggested: NonepcDNA3-HA-DDX6suggested: NonepcDNA3.1 SARS-CoV-2 N was a gift from Dr. Jeremy Luban pcDNA3.1 SARS-CoV-2suggested: RRID:Addgene_158080)Addgene plasmid #158079; http://n2t.net/addgene:158079; RRID:Addgene_158079) (38). detected: RRID:Addgene_158079)The oligonucleotides above were annealed and subcloned into the BglII-HindIII site, downstream from an RNA polymerase III promoter of pSUPER (39), to generate pSUPER-DDX1, pSUPER-DDX21, and pSUPER-MOV10, respectively. pSUPER-DDX1suggested: NonepSUPER-DDX21suggested: NonepSUPER-MOV10suggested: NoneTo construct pLV-shDDX1, pLV-shDDX21, or pLV-shMOV10, the BamHI-SalI fragments of the corresponding pSUPER plasmids were subcloned into the BamHI-SalI site of pRDI292, an HIV-1-derived self-inactivating lentiviral vector containing a puromycin resistance marker allowing for the selection of transduced cells (40). pLV-shDDX1suggested: NonepLV-shDDX21suggested: NonepLV-shMOV10suggested: NonepSUPERsuggested: RRID:Addgene_26210)pRDI292suggested: NoneWe previously described pLV-shDDX3, pLV-shDDX5, and pLV-shDDX6 (11, 12, 41) pLV-shDDX3suggested: NonepLV-shDDX5suggested: NonepLV-shDDX6suggested: NoneThe lentiviral vector particles were produced by transient transfection of the second-generation packaging construct pCMVΔR8.74 (42, 43) and the VSV-G-envelope-expressing plasmid pMD2G as well as pRDI292 into 293T cells with TransIT-LT1 transfection reagent (Mirus Bio LLC, Madison, WI, USA). pCMVΔR8.74suggested: NoneVSV-G-envelope-expressingsuggested: NonepMD2Gsuggested: NoneSoftware and Algorithms Sentences Resources CACO-2 human colon carcinoma cells (RCB0988; RIKEN BioResource Research Center, Tsukuba, Ibaraki, Japan) were cultured in DMEM supplemented with 20% FBS. RIKEN BioResourcesuggested: (RIKEN BioResource Center, RRID:SCR_003250)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on pages 56, 53, 54 and 55. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-